InMed Pharmaceuticals (INM) Status Update summary

Advances in Alzheimer's disease research

• Disease-modifying therapies are now available in several countries, marking significant progress after decades of limited treatment options.

• Mouse models have been instrumental in understanding amyloidosis and tauopathy, though they do not fully replicate human Alzheimer's pathology.

• Clinical trials now use biomarker-based patient selection, improving efficacy signals and reducing misdiagnosis.

• Removal of amyloid in humans has been shown to reduce tau and inflammatory biomarkers, but clinical impact varies among individuals.

• There is a growing emphasis on diversity in clinical trials, as genetic and biomarker differences exist across populations.

Alzheimer's disease overview and unmet needs

• Alzheimer's is a leading cause of dementia, affecting 6.9M Americans and costing $360B annually.

• Current treatments do not reverse cognitive decline and have significant limitations.

• Anti-amyloid beta monoclonal antibodies offer limited therapeutic effects and accessibility challenges.

Neuroinflammation as a therapeutic target

• Chronic neuroinflammation is recognized as a key contributor to Alzheimer's progression, with genetic and epidemiological evidence supporting its role.

• Neuroinflammation is not a linear process; it interacts with amyloid and tau pathologies in a heterogeneous and region-specific manner.

• Current non-pharmacological interventions for neuroinflammation lack strong evidence, and new drug targets are being explored, including microglia activation and cytokine pathways.

• Biomarkers for neuroinflammation, such as GFAP and YKL, are emerging but not yet standard in clinical practice.

• Drug development is increasingly focused on targeting neuroinflammation, with multiple compounds and repurposed drugs under investigation.